The effects of Remimazolam Tosilate on emergence agitation after non-cardiac thoracic surgery: A single-center, randomized, controlled clinical study.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200055164

Enrollment

Unknown

Registered

2022-01-02

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

emergence agitation

Interventions

Control Group:midazolam combined with propofol

Remimazolam Tosilate Group:Remimazolam Tosilate

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Inpatients undergoing elective thoracic surgery under general anesthesia; 2. ASA classification I-III; 3. Aged over 18 years; 4. Relevant auxiliary examinations have been completed, such as blood routine, liver and kidney function, hemostasis, etc.; 5. Those who signed the informed consent form approved by the hospital ethics committee.

Exclusion criteria

Exclusion criteria: 1.Patients with preoperative asthma, COPD or forced vital capacity in the first second (FEV1) 120 bpm and/or systolic blood pressure (BP) 180 mmHg); 5.Any signs of systemic or pulmonary infection; 6.For any other reasons, the researchers believe that it is not suitable to participate in clinical trials.

Design outcomes

Primary

Measure	Time frame
incidence of emergence agitation;	—

Countries

China

Contacts

Public ContactJin Shuqing

Shanghai Pulmonary Hospital

jinshuqing1@163.com+86 15802108819

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026